Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

BACKGROUND: Patients with triple-negative breast cancer (TNBC) are generally younger and more likely to experience disease recurrence and have the shortest survival among all breast cancer patients. Recently, neoadjuvant delivery of the programmed cell death protein-1 inhibitor pembrolizumab plus ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Javier, Haiderali, Amin, Huang, Min, Pan, Wilbur, Schmid, Peter, Akers, Katherine G., Park, Julie E., Frederickson, Andrew M., Fasching, Peter A., O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463750/
https://www.ncbi.nlm.nih.gov/pubmed/37612624
http://dx.doi.org/10.1186/s12885-023-11293-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463750/
https://www.ncbi.nlm.nih.gov/pubmed/37612624
http://dx.doi.org/10.1186/s12885-023-11293-4

Ejemplares similares